(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2009 (13.08.2009)

PCT

(10) International Publication Number
WO 2009/100324 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 37/06* (2006.01)

(21) International Application Number:
PCT/US2009/033383

(22) International Filing Date:
6 February 2009 (06.02.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/026,833 7 February 2008 (07.02.2008) US
61/042,030 3 April 2008 (03.04.2008) US

(71) Applicant *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DE WAAL MALEFYT, Rene** [NL/US]; 891 Muender Avenue, Sunnyvale, California 94086 (US). **PRESTA, Leonard, G.** [US/US]; 1900 Gough Street, #206, San Francisco, California 94109 (US).

(74) Agent: **FUENTES, Gloria**; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

[Continued on next page]

(54) **Title**: ENGINEERED ANTI-TSLPR ANTIBODIES

FIGURE 3A

```
Humanized 13H5 heavy chain VH-III
                10        20        30        40        50        60
                 *         *         *         *         *         *
13H5   QVLLKQSGPSLVQPSQSLSITCTVS GFSLSRYGVH WVRQSPGKGLEWLG VIWRSGSTDYNAAFMS
hu13H5 QVQLVESGGGVVQPGRSLRLSCAAS GFSLSRYGVH WVRQAPGKGLEWVA VIWRSGSTDYNAAFMS
                                 V                        LG               K

          70        80        90        100       110
           *         *         *         *         *
13H5   RLSITQDNSKSQVFFNMNSLQSDDSAIYYCAK KAFYVMDY WGQGTSVTVSS
hu13H5 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR KAFYVMDY WGQGTLVTVSS
        L   Q    S V                K              S
```

FIGURE 3B

```
Humanized 13H5 light chain VLK-I
                10        20        30        40        50
                 *         *         *         *         *
13H5   DIQMTQTTSSLSASLGDRVTISC RASQDISIYLN WYQQKPDGTVKLLIY YTSRLHS
hu13H5 DIQMTQSPSSLSASVGDRVTITC RASQDISIYLN WYQQKPGKAPKLLIY YTSRLHS

         60        70        80        90        100
          *         *         *         *         *
13H5   GVPSRFSGSGSGTNFSLTITNLEREDIATYFC QQGNTLPWT FGGGTKLEIKR
hu13H5 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQGNTLPWT FGQGTKVEIKR
                  N                      Q
```

(57) **Abstract**: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.

WO 2009/100324 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*